Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9AA | ISIN: US75943R1023 | Ticker-Symbol:
NASDAQ
23.04.25
21:59 Uhr
3,105 US-Dollar
0,000
0,00 %
1-Jahres-Chart
RELAY THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
RELAY THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur RELAY THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.04.Relay Therapeutics starts third layoff wave in 1 year, shedding 70 staffers7
28.02.Relay Therapeutics stock target cut to $12 at Citizens JMP13
RELAY THERAPEUTICS Aktie jetzt für 0€ handeln
26.02.Relay Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
26.02.Relay Therapeutics, Inc. - 10-K, Annual Report1
26.02.Relay Therapeutics, Inc. - 8-K, Current Report-
25.02.Relay Therapeutics Q4 2024 Earnings Preview3
19.02.Relay Therapeutics, Inc.: Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 202533
24.01.Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays' $17 Price Target25
13.01.Relay Therapeutics, Inc. - 8-K, Current Report-
10.01.Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics surges43
14.12.24Relay Therapeutics, Inc. (RLAY): A Bull Case Theory21
11.12.24Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival260New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations...
► Artikel lesen
11.12.24Relay Therapeutics, Inc. - 8-K, Current Report-
09.12.24Relay Therapeutics, Inc.: Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium4
04.12.24Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now?10
03.12.24Relay Therapeutics, Inc.: Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors175Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown...
► Artikel lesen
06.11.24Relay Therapeutics GAAP EPS of -$0.63 beats by $0.14, revenue of $0M misses by $0.08M6
06.11.24Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights172Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of...
► Artikel lesen
06.11.24Relay Therapeutics, Inc. - 8-K, Current Report-
30.10.24Relay Therapeutics, Inc.: Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 202415
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1